New biosimilar drug studied for advanced colorectal cancer
NCT ID NCT06808685
First seen Dec 29, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This study looks at how well a biosimilar version of bevacizumab (called Elovie) works and how safe it is for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 133 adults will be followed as they receive this drug as their first treatment. The goal is to see how long the treatment controls the cancer before a switch to another therapy is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Instituto Dor de Pesquisa E Ensino
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.